Cranbrook Wealth Management LLC Sells 234 Shares of Hologic, Inc. (NASDAQ:HOLX)

Cranbrook Wealth Management LLC decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 5.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,768 shares of the medical equipment provider’s stock after selling 234 shares during the quarter. Cranbrook Wealth Management LLC’s holdings in Hologic were worth $272,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of HOLX. Wolff Wiese Magana LLC bought a new position in shares of Hologic in the third quarter valued at about $25,000. General Partner Inc. bought a new position in shares of Hologic in the fourth quarter worth about $26,000. Groupama Asset Managment lifted its position in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares in the last quarter. Sunbelt Securities Inc. bought a new stake in shares of Hologic during the second quarter valued at approximately $37,000. Finally, First Horizon Advisors Inc. increased its holdings in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.75% of the stock is currently owned by insiders.

Hologic Stock Down 0.3 %

Shares of Hologic stock opened at $69.73 on Friday. The company has a market capitalization of $15.82 billion, a P/E ratio of 20.94, a price-to-earnings-growth ratio of 2.44 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The business has a 50-day moving average of $74.84 and a two-hundred day moving average of $78.34. Hologic, Inc. has a 1 year low of $68.61 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period in the prior year, the business earned $0.89 EPS. Hologic’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on HOLX shares. Raymond James increased their price objective on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Morgan Stanley lowered their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. JPMorgan Chase & Co. upped their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Wolfe Research started coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Finally, BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Seven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $88.92.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.